Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | F9 | P00740 | 2/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166739 | 0.87 | AOC3 (0.40) | XDHMCHR1MAPTF10F9 | |
| SCHEMBL4165895 | 0.85 | XDH (0.38) | XDHMCHR1MAPTGRM1 | |
| SCHEMBL4164283 | 0.85 | GRM1 (0.47) | XDHMCHR1MAPTGRM1 | |
| SCHEMBL4168810 | 0.84 | GRM1 (0.41) | XDHMCHR1MAPTGRM1TP53 | |
| SCHEMBL4163363 | 0.84 | MAPT (0.53) | MAPTGRM1TP53 | |
| SCHEMBL4161595 | 0.82 | TDP2 (0.42) | XDHMCHR1MAPTGRM1 | |
| SCHEMBL28776509 | 0.82 | XDH (0.38) | XDHMCHR1MAPTGRM1TP53 | |
| SCHEMBL1753126 | 0.81 | MAPT (0.44) | XDHMCHR1MAPTYTHDC1GRM1 | |
| SCHEMBL1753391 | 0.78 | YTHDC1 (0.51) | XDHMCHR1MAPTYTHDC1GRM1 | |
| SCHEMBL4703033 | 0.78 | DHFR (0.39) | XDHMAPTTP53CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | claimed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| EP-1999132-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM, LLC (BM) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007120454-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | CNR1, CNR2, ITPR2 | XDH 1989/4885MCHR1 1596/4885MAPT 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.